heaps of articles popping up in newspapers on stem cell treatments increasing the profile of the procedure and number of clinics adopting the technology across the US. Is only a matter of time before this feeds into revenue and hopefully profit (as a premium was paid for the US part of the medivet business - 60.5% of Medivet US, based on fairly lofty projected earnings).